Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
19 Abril 2024 - 3:26PM
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical
company developing innovative therapeutics to specifically treat
metastatic breast cancers (mBC) harboring ESR1 mutations, today
announced it will host a virtual KOL fireside chat on Monday, April
22, 2024 from noon to 1 p.m. ET, featuring Senthil Damodaran, M.D.,
Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D.
(Harvard Medical School, Massachusetts General Hospital) to discuss
the unmet need and current treatment landscape for metastatic
breast cancer. To register, click here.
The event will focus on the company's ELAINE (Evaluating
Lasofoxifene in ESR1 Mutations) studies investigating lasofoxifene
in patients with locally advanced or metastatic estrogen
receptor-positive/human epidermal growth factor 2-negative
(ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1)
mutation.
With Phase 2 ELAINE-1 and ELAINE-2 studies both completed and
having demonstrated compelling anti-tumor activity against tumors
with increasingly prevalent ESR1 mutations, enrollment is currently
open for ELAINE-3, a large, randomized, Phase 3 study with clinical
trial sites across the United States, Europe, Asia-Pacific, Israel,
and Canada.
A live question and answer session will follow the formal
presentations.
About Senthil Damodaran, M.D., Ph.D.Senthil
Damodaran, M.D., Ph.D. is an associate professor in breast medical
oncology with a joint appointment in Investigational Cancer
Therapeutics at the MD Anderson Cancer Center. His research focuses
on 1) biomarker-driven clinical trials, 2) application of omics for
target discovery in breast cancers, and 3) characterization of
secondary drug resistance mechanisms. At MD Anderson, he leads the
department’s biomarker-directed clinical and translational efforts
and serves as the lead for multiple biomarker-enriched clinical
studies including CTEP and ETCTN trials. Dr. Damodaran also serves
on the American Society of Clinical Oncology and American Board of
Internal Medicine expert panels.
About Seth Wander, M.D., Ph.D.Seth Wander,
M.D., Ph.D. is a medical oncologist at the Massachusetts General
Hospital with a clinical and translational research interest in
breast cancer and cancer genomics. Dr. Wander completed his
undergraduate degree at Cornell University, where he studied
Molecular and Cell Biology and graduated magna cum laude with
distinction in research. He pursued his M.D. and Ph.D. in Cancer
Biology at the University of Miami. Dr. Wander completed his
internship and residency in internal medicine at the Massachusetts
General Hospital and his fellowship training in medical oncology at
the Dana-Farber Cancer Institute and the Massachusetts General
Hospital Cancer Center.
Dr. Wander is active in both the clinic and laboratory, where
his research interests involve genomic mechanisms of resistance to
targeted therapies in metastatic breast cancer. Dr. Wander has
published more than forty peer-reviewed manuscripts focused on the
emerging field of precision medicine and related topics in
oncology. His research is focused on leveraging genetic and
molecular sequencing results to understand how cancers become
resistant to standard therapies in order to develop novel,
personalized treatment strategies. He is an assistant professor of
medicine at Harvard Medical School and remains engaged in teaching
medical students, residents, and fellows. He was a recipient of the
2017 Dana-Farber Cancer Institute Wong Family Translational
Research Award and a 2018 recipient of the Conquer Cancer
Foundation/American Society of Clinical Oncology Young Investigator
Award. Dr. Wander, as part of a multidisciplinary team, leads a
variety of clinical trials focused on developing novel clinical
strategies for patients with metastatic breast cancer and
resistance to standard hormonal and targeted agents. He has
presented educational sessions and original research both
nationally and internationally related to drug resistance and the
development of personalized treatment strategies for breast
cancer.
About SermonixSermonix Pharmaceuticals Inc. is
a privately held biopharmaceutical company focused on the
development of female-specific oncology products and is currently
undertaking two Phase 2 clinical studies of lasofoxifene, its lead
investigational drug. The Sermonix management team, led by founder
Dr. David Portman, has significant experience in all stages of the
drug development, regulatory and commercialization processes. Paul
Plourde, M.D., vice president of oncology clinical development, has
many decades of experience at AstraZeneca in the breast cancer drug
development arena. Barry Komm, Ph.D., chief scientific officer, is
recognized for his expertise in nuclear receptor biology. Miriam
Portman, M.D., is co-founder and chief operating officer, with
expertise in clinical trial conduct and patient recruitment.
Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development
officer, has extensive experience in pharmaceutical drug
commercialization. Simon Jenkins, Ph.D., vice president of
operations, has over 30 years of experience in global drug
development leadership. Sermonix non-executive chairman of the
board is Anthony Wild, Ph.D., former president of both Parke-Davis
Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn
more at SermonixPharma.com.
Sermonix Contact:Elizabeth Attias, Sc.D.Chief
Strategy and Development OfficerEAttias@sermonixpharma.com(973)
723-7832